Long-term bone marrow culture-derived stromal fibroblasts as a potential target for gene therapy in acute myelogenous leukemia

Yoo Hong Min, Guang Xun Li, Joon Ho Jang, Hyung Chan Suh, Jinseok Kim, June Won Cheong, Seung Tae Lee, Jee Sook Hahn, Yun Woong Ko

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

As a part of our continuing efforts to develop gene therapy for acute myelogenous leukemia (AML), this study was undertaken to evaluate the possibility of using autologous bone marrow stromal fibroblasts (BMSFs) as a target cell population. Autologous BMSFs in AML were isolated from the stromal layers of long-term bone marrow culture (LTBMC) using immunomagnetic beads. BMSFs exhibited rapid proliferation even in the absence of growth factors. Cultures stimulated with bFGF produced significantly increased numbers of BMSFs than cultures without added growth factors. Using LNC/LacZ retroviral vector, the transduction efficiecy of BMSFs was 13 ± 4% at a 5 multiplicity of infection (MOI). LNC/interleukin-2 (IL-2)-transduced BMSFs produced between 1200 and 4800pg of IL-2/106 cells per 24h. Using adenoviral vector AdV/LacZ, the transduction efficiency was 84 ± 10% at 100, and 92 ± 8% at a MOI of 1000. Although the addition of basic fibroblast growth factor, epidermal growth factor, or platelet-derived growth factor did not affect the transduction efficiency, they increased the numbers of transduced cells significantly (P < 0.01). AdV/IL-2-treated BMSFs produced high levels of IL-2 over the course of 7 days between 9820 and 22,700pg of IL-2/106 cells per 24h. Our finding that the genetically engineered autologous BMSFs of AML could be successfully established in vitro implies that BMSFs obtained from LTBMC might be considered as a target cell population for certain types of clinical gene therapy in AML.

Original languageEnglish
Pages (from-to)369-376
Number of pages8
JournalLeukemia Research
Volume26
Issue number4
DOIs
Publication statusPublished - 2002 Feb 23

Fingerprint

Acute Myeloid Leukemia
Genetic Therapy
Fibroblasts
Bone Marrow
Interleukin-2
Health Services Needs and Demand
Intercellular Signaling Peptides and Proteins
Platelet-Derived Growth Factor
Fibroblast Growth Factor 2
Infection
Epidermal Growth Factor
Cell Count

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Min, Yoo Hong ; Li, Guang Xun ; Jang, Joon Ho ; Suh, Hyung Chan ; Kim, Jinseok ; Cheong, June Won ; Lee, Seung Tae ; Hahn, Jee Sook ; Ko, Yun Woong. / Long-term bone marrow culture-derived stromal fibroblasts as a potential target for gene therapy in acute myelogenous leukemia. In: Leukemia Research. 2002 ; Vol. 26, No. 4. pp. 369-376.
@article{11076c7b3a2e4a5daf714c4acc0fc77e,
title = "Long-term bone marrow culture-derived stromal fibroblasts as a potential target for gene therapy in acute myelogenous leukemia",
abstract = "As a part of our continuing efforts to develop gene therapy for acute myelogenous leukemia (AML), this study was undertaken to evaluate the possibility of using autologous bone marrow stromal fibroblasts (BMSFs) as a target cell population. Autologous BMSFs in AML were isolated from the stromal layers of long-term bone marrow culture (LTBMC) using immunomagnetic beads. BMSFs exhibited rapid proliferation even in the absence of growth factors. Cultures stimulated with bFGF produced significantly increased numbers of BMSFs than cultures without added growth factors. Using LNC/LacZ retroviral vector, the transduction efficiecy of BMSFs was 13 ± 4{\%} at a 5 multiplicity of infection (MOI). LNC/interleukin-2 (IL-2)-transduced BMSFs produced between 1200 and 4800pg of IL-2/106 cells per 24h. Using adenoviral vector AdV/LacZ, the transduction efficiency was 84 ± 10{\%} at 100, and 92 ± 8{\%} at a MOI of 1000. Although the addition of basic fibroblast growth factor, epidermal growth factor, or platelet-derived growth factor did not affect the transduction efficiency, they increased the numbers of transduced cells significantly (P < 0.01). AdV/IL-2-treated BMSFs produced high levels of IL-2 over the course of 7 days between 9820 and 22,700pg of IL-2/106 cells per 24h. Our finding that the genetically engineered autologous BMSFs of AML could be successfully established in vitro implies that BMSFs obtained from LTBMC might be considered as a target cell population for certain types of clinical gene therapy in AML.",
author = "Min, {Yoo Hong} and Li, {Guang Xun} and Jang, {Joon Ho} and Suh, {Hyung Chan} and Jinseok Kim and Cheong, {June Won} and Lee, {Seung Tae} and Hahn, {Jee Sook} and Ko, {Yun Woong}",
year = "2002",
month = "2",
day = "23",
doi = "10.1016/S0145-2126(01)00134-5",
language = "English",
volume = "26",
pages = "369--376",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "4",

}

Long-term bone marrow culture-derived stromal fibroblasts as a potential target for gene therapy in acute myelogenous leukemia. / Min, Yoo Hong; Li, Guang Xun; Jang, Joon Ho; Suh, Hyung Chan; Kim, Jinseok; Cheong, June Won; Lee, Seung Tae; Hahn, Jee Sook; Ko, Yun Woong.

In: Leukemia Research, Vol. 26, No. 4, 23.02.2002, p. 369-376.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term bone marrow culture-derived stromal fibroblasts as a potential target for gene therapy in acute myelogenous leukemia

AU - Min, Yoo Hong

AU - Li, Guang Xun

AU - Jang, Joon Ho

AU - Suh, Hyung Chan

AU - Kim, Jinseok

AU - Cheong, June Won

AU - Lee, Seung Tae

AU - Hahn, Jee Sook

AU - Ko, Yun Woong

PY - 2002/2/23

Y1 - 2002/2/23

N2 - As a part of our continuing efforts to develop gene therapy for acute myelogenous leukemia (AML), this study was undertaken to evaluate the possibility of using autologous bone marrow stromal fibroblasts (BMSFs) as a target cell population. Autologous BMSFs in AML were isolated from the stromal layers of long-term bone marrow culture (LTBMC) using immunomagnetic beads. BMSFs exhibited rapid proliferation even in the absence of growth factors. Cultures stimulated with bFGF produced significantly increased numbers of BMSFs than cultures without added growth factors. Using LNC/LacZ retroviral vector, the transduction efficiecy of BMSFs was 13 ± 4% at a 5 multiplicity of infection (MOI). LNC/interleukin-2 (IL-2)-transduced BMSFs produced between 1200 and 4800pg of IL-2/106 cells per 24h. Using adenoviral vector AdV/LacZ, the transduction efficiency was 84 ± 10% at 100, and 92 ± 8% at a MOI of 1000. Although the addition of basic fibroblast growth factor, epidermal growth factor, or platelet-derived growth factor did not affect the transduction efficiency, they increased the numbers of transduced cells significantly (P < 0.01). AdV/IL-2-treated BMSFs produced high levels of IL-2 over the course of 7 days between 9820 and 22,700pg of IL-2/106 cells per 24h. Our finding that the genetically engineered autologous BMSFs of AML could be successfully established in vitro implies that BMSFs obtained from LTBMC might be considered as a target cell population for certain types of clinical gene therapy in AML.

AB - As a part of our continuing efforts to develop gene therapy for acute myelogenous leukemia (AML), this study was undertaken to evaluate the possibility of using autologous bone marrow stromal fibroblasts (BMSFs) as a target cell population. Autologous BMSFs in AML were isolated from the stromal layers of long-term bone marrow culture (LTBMC) using immunomagnetic beads. BMSFs exhibited rapid proliferation even in the absence of growth factors. Cultures stimulated with bFGF produced significantly increased numbers of BMSFs than cultures without added growth factors. Using LNC/LacZ retroviral vector, the transduction efficiecy of BMSFs was 13 ± 4% at a 5 multiplicity of infection (MOI). LNC/interleukin-2 (IL-2)-transduced BMSFs produced between 1200 and 4800pg of IL-2/106 cells per 24h. Using adenoviral vector AdV/LacZ, the transduction efficiency was 84 ± 10% at 100, and 92 ± 8% at a MOI of 1000. Although the addition of basic fibroblast growth factor, epidermal growth factor, or platelet-derived growth factor did not affect the transduction efficiency, they increased the numbers of transduced cells significantly (P < 0.01). AdV/IL-2-treated BMSFs produced high levels of IL-2 over the course of 7 days between 9820 and 22,700pg of IL-2/106 cells per 24h. Our finding that the genetically engineered autologous BMSFs of AML could be successfully established in vitro implies that BMSFs obtained from LTBMC might be considered as a target cell population for certain types of clinical gene therapy in AML.

UR - http://www.scopus.com/inward/record.url?scp=0036171975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036171975&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(01)00134-5

DO - 10.1016/S0145-2126(01)00134-5

M3 - Article

C2 - 11839380

AN - SCOPUS:0036171975

VL - 26

SP - 369

EP - 376

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 4

ER -